Antibody phage display technology has supported the emergence of numerous therapeutic antibodies. The development of bispecific antibodies, a promising new frontier in antibody therapy, could be facilitated by new phage display approaches that enable pairs of antibodies to be coselected based on co-engagement of their respective targets. We describe such an approach, making use of two complementary leucine zipper domains that heterodimerize with high affinity. Phagemids encoding a first antibody fragment (scFv) fused to phage coat protein via the first leucine zipper are rescued in bacteria expressing a second scFv fused to the second leucine zipper as a soluble periplasmic protein, so that it is acquired by phage during assembly. Using a soluble scFv specific for a human CD3-derived peptide, we show that its acquisition by phage displaying an irrelevant antibody is sufficiently robust to drive selection of rare phage (1 in 10 5 ) over three rounds of panning. We then set up a model selection experiment using a cell line expressing the chemokine receptor CCR5 fused to the CD3 peptide together with a panel of phage clones capable displaying either an anti-CCR5 scFv or an irrelevant antibody, with or without the capacity to acquire the soluble anti-CD3 scFv. In this experiment we showed that rare phage (1 in 10 5 ) capable of displaying the two different scFvs can be specifically enriched over four rounds of panning. This approach has the potential to be applied to the identification of pairs of ligands capable of co-engaging two different user-defined targets, which would facilitate the discovery of novel bispecific antibodies.
Introduction
Phage display is a powerful in vitro evolution technology that enables rare ligands with desired characteristics to be isolated from large libraries of variants encoded by and expressed at the surface of filamentous bacteriophage. Isolation of ligands is typically achieved through successive rounds of panning of the phage library against a single purified and immobilized target structure (Pande et al., 2010) . Antibody phage display has been a particularly successful branch of the technology (Bradbury and Marks, 2004) , with a number of antibodies originally isolated by phage display now in use as therapeutics, and many more in clinical development (Nixon et al., 2014) .
Bispecific antibodies represent a new frontier for the development of novel therapeutic antibodies (Kontermann and Brinkmann, 2015) , While a great deal of effort has been focused on the exploration of different bispecific antibody scaffolds and to support manufacturing strategies (Klein et al., 2012; Spiess et al., 2013 Spiess et al., , 2015 Rouet and Christ, 2014) , little emphasis has been placed on optimizing the initial discovery process. While conventional antibody phage display has been successfully used in the discovery of bispecific antibodies (Fischer et al., 2015) , selection campaigns could potentially be streamlined by adapting the technology so that selection during panning is driven by co-engagement of the two chosen targets by two different antibodies displayed on the same phage particle.
Phage diabody technology, in which libraries of scFv dimers presenting two different geometrically opposed antigen binding sites are displayed on phage (McGuinness et al., 1996) , could in principle be used for selection experiments based on co-engagement. However, in the only published application of the technology, selection was achieved by panning sequentially on one antigen followed by the other rather than direct selection based on co-engagement of the two target structures (McGuinness et al., 1996) . Broader application of phage diabody technology may not be possible due to difficulties in constructing diabody repertoires, and differences in the antigen binding site geometry of diabodies versus immunoglobulin molecules may compromise their utility for translation into immunoglobulin-based bispecific antibody formats.
We designed a new method for the dual display of single chain Fv (scFv) antibody fragments in which leucine zipper heterodimerization domains are used to present two different scFvs are together at the phage surface in a geometry more similar to that of intact immunoglobulin than in the diabody format, making use of a dual replicon system that is readily compatible with the use of large naïve antibody repertoires. We assessed the potential of this approach for use in selecting rare phage clones on the basis of their ability to coengage two different user-defined targets.
Materials and Methods

Plasmids, phagemids, helper phage and bacterial strains
The plasmids pCDNA3.1 and pCDF-1b were purchased from Invitrogen and Novagen, respectively. The phagemid vector pNDS has been described previously (Venet et al., 2012) . Helper phage M13KO7 (Vieira and Messing, 1987) 
were produced internally. E. coli XL1-Blue (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac) was purchased from Agilent Technologies.
Antibodies, cell lines and materials
Antibodies Anti-human CXCL10 (Fagete et al., 2009 ) and anti-human IFNγ (Ravn et al., 2010) antibodies were isolated from naïve scFv phage display libraries using standard phage display selection and screening procedures. Genes encoding VH and VL domains of previously described antibodies directed against human CCR5 (Trkola et al., 2001) and residues 1-15 of the mature form of the human CD3 epsilon subunit (Kufer et al., 2011) were synthesized (Eurofins) and assembled as scFv fragments. Binding affinities (K d ) of intact human IgG proteins derived from these scFvs, determined using surface plasmon resonance, are as follows: anti-CXCL10: 0.2 nM, Anti-IFNγ: 0.25 nM, and anti-CD3: 7 nM. The binding affinity of the humanized PRO-140 antibody has not been measured directly, but the binding affinity of the murine IgG from which it was derived was compared to those of other murine anti-CCR5 monoclonal antibodies in a competition binding assay with HIV envelope glycoprotein, where an IC 50 value comparable to that of the extensively studied anti-CCR5 monoclonal antibody, 2D7, was obtained (Olson et al., 1999) .
CHO-CD3-CCR5 cells
A fusion construct encoding human CCR5 preceded by the human prolactin leader sequence and 1-15 of the mature form of the human CD3 epsilon subunit was cloned into the mammalian cell expression vector pCDNA3.1. The resulting plasmid was used to transfect Chinese Hamster Ovary (CHO) cells, which were then amplified in the presence of the selection antibiotic G418 (Invitrogen, 1.2 mg/mL). Individual clones were isolated by cell sorting followed by further expansion, with a single clone chosen based on flow cytometry analysis of surface expression of both CCR5 and the CD3 epsilon subunit peptide epitope. Further details are provided in the Supplementary Information.
Biotinylated CD3 peptide-Fc PCR extension was used to fuse the sequence encoding residues 1-15 of human CD3 epsilon to the N-terminus of the human γ1 Fc region and incorporate a C-terminal AviTag™ sequence (Avidity). This fragment was cloned into the Peak8 mammalian expression vector (Edge Biosystems) using HindIII and EcoRI sites, and the fusion protein was expressed as described previously (Magistrelli et al., 2010) . After 10 days production in a CELLine bioreactor (Integra), the harvested protein was purified on a protein G Sepharose column (GE healthcare) using an ÄKTA Prime chromatography system (Amersham Pharmacia Biotech). The purified protein was biotinylated in vitro by using BirA enzyme (Avidity) according to the manufacturer's instructions, desalted using a PD10 column (GE healthcare), and verified for purity and integrity by SDS-PAGE.
Cloning dual replicon constructs
Dual display phagemid (pNDS-DD) The phagemid pNDS was modified using a QuikChange cloning strategy (Agilent Technologies) to introduce SpeI and PacI sites in frame with the phage gene 3 coding sequence and remove the amber codon. The SpeI and PacI sites were then used to insert fragments corresponding to E. coli codon-optimized coding sequences corresponding to Z1 and Z2 leucine zipper domains (Moll et al., 2001) and flanked by glycine/serine-rich spacers. Antibody scFv fragments were then cloned into dual display phagemids using the standard SfiI and NotI sites in the phagemid backbone. Further details are provided in the Supplementary Information.
Plasmid for soluble component expression (pCDF-1b-DD)
A SphI restriction site was inserted upstream of the multiple cloning site of pCDF-1b using QuikChange mutagenesis (Agilent Technologies). This site, together with the PacI site in the plasmid backbone, was used to insert SphI-PacI fragments from donor phagemid vectors corresponding to the encoded scFv-leucine zipper fusion proteins. Further details are provided in the Supplementary Information.
Phage rescue
pNDS-DD Phagemids introduced into E. coli TG1 harboring pCDF1b-DD plasmids were rescued using M13KO7 helper phage according to standard procedures (Hoogenboom et al., 1991) , except that spectinomycin (30 μg/mL), the selection antibiotic on the pCDF-1b-DD plasmid, was used in addition to ampicillin (100 μg/mL) and kanamycin (50 μg/mL).
Rescued phage were precipitated twice by incubating rescue supernatant for 2 h at 4°C with a volume of polyethylene glycol 8000 (20% (w/v), Acros Organics)/2.5 M NaCl solution corresponding to 30% of the rescue supernatant volume. Precipitates were then resuspended in 10 mM Tris-HCL buffer (pH 8.0) supplemented with 1 mM EDTA (Tris-EDTA buffer).
Phage ELISA
Maxisorp plates (Nunc) were coated (4°C, overnight) with 1 μg/mL streptavidin (Roche), then washed three times with PBS supplemented with 0.05% Tween 20 (PBS-Tween 0.05%) and blocked with PBS supplemented with 3% (w/v) milk powder (Sigma) (PBS-milk). Plates were washed 3 times with PBS-Tween 0.05% before incubation at ambient temperature for 1 h with biotinylated CD3 peptideFc (1 μg/mL). Plates were then washed with 3 times with PBS-Tween 0.05% and incubated (ambient temperature, 1 h) with approximately 10 10 cfu rescued phage suspended in PBS-milk. After three washes with PBS-Tween 0.05%, plates were incubated at ambient temperature for 1 h with horseradish peroxidase-conjugated anti-M13 antibody (1:5000, Amersham). Plates were then washed five times with PBS-Tween 0.05% and revealed using TMB substrate (Sigma-Aldrich), with the reaction stopped after 20 min with 1 M H 2 SO 4 prior to absorbance measurement at 450 nm.
Panning selection against immobilized CD3 peptide
Phage mixtures (10 12 cfu) were suspended in 1 mL PBS-milk and preadsorbed (ambient temperature, 1 h) on streptavidin magnetic beads (Dynal M-280). A separate batch of streptavidin magnetic beads (100 μL) was blocked with PBS-milk for 1 h at ambient temperature and coated with biotinylated CD3 peptide-Fc (100 nM, ambient temperature, 1 h). Beads were then washed first with 1 mL PBS supplemented with 0.1% Tween 20 (PBS-Tween 0.1%), then with 1 mL PBS and finally with 1 mL PBS-milk prior to incubation (ambient temperature, 2 h) with the pre-adsorbed phage. The beads were then washed with PBS-Tween 0.1% (five times) followed by PBS (twice) and then incubated for one hour at 37°C with exponentially growing E. coli TG1. The bacterial culture was then spread on to plates containing 2xTY agar supplemented with ampicillin and glucose.
Co-engagement selection
This procedure is schematically represented in Fig. 4B .
Blocking phage
Phage mixtures (approx. 10 11 cfu for the first round, then 10 9 -10 10 cfu for subsequent rounds) were blocked in 300 μL PBS supplemented with bovine serum albumin (3% (w/v) Sigma) at ambient temperature for 1 h on a rotary shaker (20 rpm).
Pre-adsorption on untransfected CHO cells
The blocked phage mixture was used to resuspend 10 7 untransfected CHO cells, with the resulting suspension kept on ice for 1 h. The suspension was then centrifuged at 300 g (4°C, 3 min), and the supernatant containing cell-free phage was recovered.
Incubation with CHO-CD3-CCR5 cells
The recovered supernatant was used to resuspend 10 7 CHO CCR5-CD3 cells, with the resulting suspension was incubated at 4°C for 2 h on a rotary shaker (10 rpm) then washed with 1 mL ice cold PBSTween 0.05% (four times) followed by 1 mL ice cold PBS (twice).
Low pH elution
The cell suspension was centrifuged at 300 g (4°C, 3 min), then resuspended in 500 μL Glycine HCl buffer (0.2 M pH 2.2) and left for 10 min on ice prior to neutralization with Tris-EDTA buffer. It was again centrifuged (300 g, 4°C, 3 min), with both the supernatant containing acid-eluted phage and the cell pellet recovered separately.
Cell lysis elution and infection of E. coli Pelleted cells were resuspended in 500 μL Tris-EDTA and lysed using three rapid freeze-thaw cycles. The lysates, either combined with the acid elutions (selection Rounds 2-4) or used alone (Round 1), were added to 10 mL of exponentially growing E. coli TG1 cells and incubated at 37°C, for 1 h. The resulting bacterial culture was spread on plates containing 2xTY agar supplemented with ampicillin and glucose.
Sequencing of individual phage colonies
After each round of selection, unique E. coli TG1 colonies harboring individual phage clones were picked and cultured overnight in LB broth supplemented with ampicillin and glucose. Plasmid minipreps were prepared and used for insert sequencing (Microsynth). Analysis of the resulting sequences was used to determine both the scFv and the leucine zipper domain encoded on each phagemid clone.
Results
Building a dual replicon system based on leucine zipper heterodimerization domains
For display of two different scFvs in proximity at the phage surface, we designed a dual replicon system based on a pair of leucine zipper domains (Moll et al., 2001 ) that feature complementary charged residues so that homodimerization is inhibited by electrostatic repulsion and heterodimerization is favored by electrostatic attraction (Z1 and Z2, Fig. 1A ). Construction of each replicon is described in the Material and Methods section, with further information provided in Supplementary Information. In the first of the two replicons, one leucine zipper domain is inserted between a first scFv fragment and the phage pIII minor coat protein on a phagemid vector (pNDS-DD) so that both the gene and its product are incorporated into phage particles during rescue (subsequently referred to as the 'phage component'). In the second replicon (pCDF-1b-DD), the other leucine zipper domain is appended to a second scFv fragment that is encoded for expression as a soluble periplasmic protein (subsequently referred to as the 'soluble component').
The pCDF-1b-DD plasmid does not contain a filamentous phage origin of replication and so is not packaged into phage particles.
We hypothesized that during phage assembly and extrusion, the soluble component would form a stable leucine zipper-mediated complex with the phage component in the bacterial periplasm resulting in phage particles displaying two different antibody fragments: the phage component scFv encoded on the packaged phagemid vector plus the soluble component scFv encoded on the plasmid harbored by the bacterial host in which phage rescue is performed (Fig. 1B) .
Characterization of dual display phage
For this study, three antibody fragments of known specificity were used to test the feasibility of dual display: anti-CXCL10 (Fagete et al., 2009) , anti-interferon gamma (anti-IFNγ) (Ravn et al., 2010) and anti-CD3 peptide (Kufer et al., 2011) . In a first experiment, four pNDS-DD phagemid constructs encoding anti-IFNγ-Z1, anti-IFNγ-Z2, anti-CXCL10-Z1 or anti-CXCL10-Z2 were used for the expression of phage components. These phagemids were rescued in E. coli harboring pCDF-1b-DD plasmids encoding either anti-CD3-Z1 or anti-CD3-Z2 as soluble components. The eight different phage rescue mixtures were assessed by ELISA for their capacity to bind to an immobilized CD3 peptide-Fc fusion protein (Fig. 2) .
Importantly, positive ELISA signals were only obtained when the soluble component leucine zipper domain was complementary to the leucine zipper domain on the phage component (i.e. Z1 on the phage component, Z2 on the soluble component or vice versa; Fig. 2 ), confirming that incorporation of the soluble antibody fragment for dual display is driven by heterodimerization of complementary leucine zipper domains. We were unable to measure the binding affinity of either the anti-CD3-Z1 or the anti-CD3-Z2 scFv fusion proteins because when produced in isolation they showed low expression levels and problems of solubility. Nonetheless, our results indicate that in the dual display phage setting, the low expression levels are compatible with functional association into phage particles, and suggest that the solubility issues, likely due to the presence of unpaired leucine zipper domains, might be alleviated through heterodimerization with the partner leucine zipper on the phage particle.
Incorporation of the soluble component antibody is sufficient to drive phage selection
We next performed an experiment to determine whether leucine zipper-mediated acquisition of the soluble component scFv during phage assembly is sufficiently robust to drive phage selection during cycles of panning against its target. pNDS-DD phagemids, encoding either anti-IFNγ-Z1 or anti-IFNγ-Z2 as the phage component, were rescued in E. coli harboring pCDF-1b-DD encoding the anti-CD3-Z1 soluble component. In this way, only the anti-IFNγ-Z2 phage would be capable of acquiring the anti-CD3 scFv through leucine zipper heterodimerization (Fig. 3A) . This mixture of phage was subjected to rounds of selection panning against immobilized CD3 peptide-Fc fusion protein in order to determine the extent to which anti-CD3-displaying anti-IFNγ-Z2 phage could be enriched from a background of anti-CD3 negative anti-IFNγ-Z1 phage. To control for any enrichment occurring because of possible growth advantage differences between anti-IFNγ-Z1 and anti-IFNγ-Z2 phage, we performed a parallel selection experiment in which rounds of infection and amplification were performed without the CD3 peptide panning step.
After each round of selection, individual colonies for each phage population were sequenced to determine the proportion of anti-IFNγ-Z2 phage with respect to anti-IFNγ-Z1 (Table I) , and assessed by ELISA for binding to immobilized CD3 peptide-Fc fusion protein ( Fig. 3B and C) . The anti-IFNγ-Z2 phage, which are capable of acquiring the anti-CD3-Z1 soluble component antibody through leucine zipper heterodimerization, were efficiently enriched during panning against the immobilized CD3 peptide (Table I) . As expected, this enrichment was accompanied by increased anti-CD3 phage ELISA signals (Fig. 3B) . No increase in either Z2 leucine zipper prevalence or anti-CD3 peptide ELISA signal were noted when phage were subjected to rounds of selection in the absence of panning (Fig. 3C) . Hence, association of the soluble component antibody in the dual display system is sufficiently robust to drive selection over several rounds of panning. 
Selection driven by co-engagement of two targets by the two displayed antibodies
We next set out to test whether selection of dual display phage could be driven by co-engagement of two different target epitopes. We generated a clonal cell line (CHO-CD3-CCR5) stably expressing a cell surface receptor, CCR5, with the CD3 epsilon (1-15) peptide appended to its extracellular N-terminal domain (Fig. 4A ). Having reformatted a well characterized anti-CCR5 antibody (PRO-140, (Trkola et al., 2001) ) as a scFv fragment, we used the cell line in a selection experiment involving phage clones encoding four different phage components: anti-CCR5-Z1, anti-CCR5-Z2, anti-IFNγ-Z1 and anti-IFNγ-Z2.
After rescue in E. coli expressing anti-CD3-Z1 soluble component, each of the four phage clones would be expected to display a different combination of antibodies: anti-CCR5-Z2 phage with both anti-CCR5 and anti-CD3 antibodies, anti-CCR5-Z1 phage with anti-CCR5 only, anti-IFNγ-Z2 phage with anti-CD3 only, and anti-IFNγ-Z1 with neither cognate antibody (Fig. 4A) . The cognate phage clones (anti-CCR5-Z2, anti-CCR5-Z1 and anti-IFNγ-Z2) were each diluted ten-thousand-fold with respect to the non-cognate Fig. 3 Phage selection is driven by the incorporated soluble component antibody. (A) Experimental set up. Phage clones encoding either anti-IFNγ-Z1 or anti-IFNγ-Z2 as the phage component were subjected to rounds of selection consisting of infection and rescue in E. coli expressing anti-CD3-Z2 as the soluble component followed by panning against immobilized CD3 peptide. Only phage with the anti-IFNγ-Z2 phage component would be expected to have the capacity to acquire the anti-CD3-Z1 soluble component. (B) Anti-IFNγ-Z2 phage (capable of acquiring the anti-CD3-Z1 soluble component) were mixed with anti-IFNγ-Z1 phage (incapable of acquiring the anti-CD3-Z1 soluble component) at the indicated ratios and ELISA assay for binding to immobilized CD3 peptide was performed on the phage mixture prior to (R0) and following rounds of selection on immobilized CD3 peptide. (C) ELISA assay as in B except that selection rounds were carried out without the panning step on immobilized CD3 peptide.
clone (anti-IFNγ-Z1) and subjected to rounds of panning on CHO-CD3-CCR5 cells (Fig. 4B) .
Analysis of enrichment was carried out by sequencing randomly picked colonies after selection Rounds 3 and 4 (Table II) . As expected, the non-cognate phage clone (anti-IFNγ-Z1), which was initially present at a 10 000-fold excess, was progressively eliminated during successive rounds of selection. Importantly, of the phage clones displaying one or more cognate antibodies, only the clone displaying both anti-CD3 and anti-CCR5 (anti-CCR5-Z2) was enriched during selection: anti-CCR5-Z2 was the only one of the four starting clones that was detectable after Round 4. Hence dual display can be used to specifically enrich rare phage (i.e. present at 1 in 10 5 in the initial population) capable of displaying antibodies against two different target structures.
Discussion
In this study, we describe a new method that enables robust display of two different antibody fragments on the surface of filamentous bacteriophage with a format resembling that of the two antigen binding sites on an intact immunoglobulin molecule. A first antibody fragment, the phage component, is joined to the phage minor coat protein g3p as in standard phage antibody display, except that the fusion protein incorporates a leucine zipper domain. This enables acquisition of a second antibody fragment (soluble component), which is expressed in the same bacterial cell during phage production and carries a complementary leucine zipper domain for heterodimerization. A number of technologies have been described that make use of leucine zipper homo-or heterodimerization to assemble bivalent antibodies (with a single specificity) for phage display (Lee et al., 2004) or to assemble bispecific antibodies from either scFv or Fab antibody fragments (Kostelny et al., 1992; de Kruif and Logtenberg, 1996; Christopherson et al., 2007) . None of these approaches involved assembly of two different antibody fragments for phage display, however.
Our preliminary evaluation of the approach focused on the association of the soluble component antibody during phage assembly, indicating that it is dependent on leucine zipper heterodimerization, as expected (Fig. 2) , and robust enough to drive the selection of rare (i.e. present at 1 in 10 5 in the initial population) heterodimerizationcompetent phage clones through several rounds of panning against the target of the soluble component antibody (Fig. 3 , Table I ). We then demonstrated that rare clones (1 in 10 5 ) capable of displaying two different antibody specificities can be isolated over several rounds of selection based on their ability to co-engage two user-defined targets (Fig. 4 , Table II ), thereby providing an important initial proof of concept. Presumably, the extra avidity provided by co-engagement of the two adjacent targets provided dual display phage with a selection advantage under the stringent selection conditions used in this experiment. While the model selection experiments performed in this study indicate that dual display of two different antibody fragments is feasible using this system, further optimization might lead to enhanced performance. For example, in the dual display expression vectors the leucine zipper domains were flanked by short flexible linkers (SGGGG and VGGSL); increasing linker length might increase the accessibility of the antibody fragments to their respective antigens, facilitating binding.
The dual replicon strategy that we adopted was designed to make the dual display system readily amenable to library-based selection. A 'single pot' dual display naïve antibody library could be cloned into the pNDS-DD phagemid and then used with different user-defined soluble component antibodies: all that would be required is for a new bacterial strain harboring the soluble component antibody fragment of choice to be generated, infected by the dual display naïve antibody library and then subjected to rescue by helper phage. Success in model dual selection experiment on CD3 peptide-tagged CCR5 suggests that it should be possible to generate new anti-CCR5 antibodies using such a dual display antibody library with the anti-CD3 antibody fragment as the soluble component. Such a 'guided selection' approach would be of value in selection campaigns to isolate antibodies specific for complex transmembrane proteins presented at the cell surface, and would complement other selection approaches (Osbourn et al., 1998a (Osbourn et al., , 1998b Osbourn, 2002) that have been developed to address this challenge.
In its current format, in which the phage component antibody gene alone is encoded on the phage particle, combinatorial screening to search for novel pairs of compatible antibodies is not possible. This limitation could in principle be overcome through the use of LoxP/Cre combinatorial infection/in vivo recombination (Waterhouse et al., 1993; Griffiths et al., 1994; Fisch et al., 1996; Sblattero and Bradbury, 2000) , in which ligand-encoding sequences are transfered from one replicon to another within bacteria expressing Cre-recombinase. Combinatorial dual display phagemid libraries encoding both soluble and phage component antibodies could be generated by adapting the pNDS-DD and pCDF-1b-DD vectors to include appropriate flanking recombination sites and introduced into an E. coli strain expressing Cre-recombinase. In order for the total combinatorial diversity to be manageable, however, it would be necessary for the complexity of the two input libraries to be lower than that of a typical naïve phage antibody library. This could be achieved by combining two repertoires resulting from initial selection of the starting library on each of the two target antigens.
In conclusion, we have developed and performed an initial evaluation of a dual display phage antibody approach, showing that it has the potential to be used in the streamlining of bispecific antibody discovery. For example, it could be applied to the direct isolation of pairs of antibodies capable of co-engaging two different cell surface markers on tumor cells (increased target cell specificity), or pairs of antibodies capable inducing heterodimerization of two different target cell surface receptors (fine-tuning modulation of cell signaling activity).
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